The positive ENTR-601-44 data is a major catalyst but the sharp revenue decline and widening loss cap upside. Watch for upcoming ELEVATE-45-201 data in mid-2026 and further cohort readouts by year-end to validate the platform.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $6.85entry
- T+1 · 6mo ago −0.15%α −0.98% · $6.84
- T+5 · 6mo ago +6.86%α +5.36% · $7.32
- T+20 · 6mo ago −3.94%α −7.08% · $6.58
- T+60 · 4mo ago +5.99%α +2.15% · $7.26
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Entrada Therapeutics reported Q1 2026 results with a net loss of $39.7M ($0.95/share), beating consensus EPS of -$1.06 by 10.4%. Collaboration revenue plunged to $0.9M from $20.6M a year ago as the Vertex research plan completed, but the company highlighted positive clinical data from ENTR-601-44 in Duchenne muscular dystrophy, showing favorable safety and early functional benefit.
Key Financial Metrics
Key Facts
- Net loss widened to $39.7M in Q1 2026 from $17.3M in Q1 2025 due to higher R&D costs and lower collaboration revenue.
- Collaboration revenue declined to $0.9M from $20.6M YoY as the Vertex VX-670 research plan substantially completed.
- Positive topline results from ELEVATE-44-201 Cohort 1: favorable safety, statistically significant improvement in Time to Rise velocity.
- Cash, cash equivalents and marketable securities of $254.9M, expected to fund operations into Q3 2027.
- EPS of -$0.95 beat the -$1.06 consensus by 10.4%.
Financial Impact
Net loss increased 129% YoY to $39.7M; revenue decreased 96% to $0.9M.
Risk Factors
- Clinical development risk for DMD programs; reliance on positive data from ongoing and future cohorts.
- Dependence on Vertex partnership for VX-670; any setbacks could impact investor sentiment.
- Cash burn rate; runway only into Q3 2027 without additional financing or partnership milestones.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289842 |
Track record
21 reports on TRDA
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +58.22% at T+20 after the May 4, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $4.55 Now $5.00 +9.89% settles Feb 3
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $4.55 Now $5.00 +9.89% settles Jan 11
- Sep 9, 20269w ago Insider Cluster Bearish 6/10 Entry $6.42 Now $5.00 +22.12% settles Dec 4
- Sep 3, 202610w ago Insider Cluster Neutral 3/10 Entry $7.13 Now $5.00 −29.87% settles Dec 1
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 3/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $7.27 Now $5.00 −31.22% settles Nov 20
- Aug 10, 202614w ago Insider Cluster Neutral 2/10 Entry $7.04 to $5.06 Now $5.00 −28.98% ▼ −28.13% −27.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers